{"entity":{"id":"nct06115135","kind":"trial","name":"A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma","aka":[],"tldr":"A phase 2 trial of Venetoclax in multiple myeloma, run by Oncotherapeutics, now recruiting.","summary":"A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT06115135 by Oncotherapeutics, with 39 participants planned, started 2024-06-20 and due to reach its primary completion in 2026-04-30. Interventions recorded: Venetoclax. Conditions listed: Multiple Myeloma in Relapse, Multiple Myeloma, Refractory. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06115135","url":"https://clinicaltrials.gov/study/NCT06115135"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["venetoclax"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06115135","phase":"2","setting":"A Phase 2 Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma Patients With t(11;14)","sponsor":"Oncotherapeutics","enrolled":39,"outcomes":[]},"route":"/trials/nct06115135/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"drug":[{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}]}}